Tyler Flores

Facing clinical trial disappointments with its depression drug, Relmada Therapeutics is shifting focus to a promising bladder cancer treatment, NDV-01, while also advancing a program for compulsive disorders. Investors are watching closely.

Despite a revenue dip, Strata Skin Sciences is strategically positioning itself for growth with expanded CPT codes and a focus on recurring revenue. The company's innovative XTRAC system and new TheraClearX device are key to its long-term prospects.

ORIC Pharmaceuticals is making strides in metastatic castration-resistant prostate cancer with its PRC2 inhibitor, ORIC-944, and brain-penetrant lung cancer therapy, enozertinib, bolstered by a strong financial position.

Positive preclinical data for JADE101 and progress on JADE201 have secured a significant investment for Jade Biosciences, positioning the company to advance its autoimmune disease pipeline.

Positive clinical trial results for telitacicept in Sjögren's disease and continued promise in myasthenia gravis, coupled with a significant capital raise, position Vor Bio for potential growth – despite substantial net losses.

NeOnc Technologies completes enrollment in its Phase 2a trial of NEO100, a novel treatment for aggressive brain cancer utilizing intranasal delivery to bypass the blood-brain barrier. Preliminary data expected in Q2 2026.

Positive trial results for prostate cancer, expansion into NSCLC, and a significant debt financing position Candel Therapeutics for a pivotal year in oncology innovation.

Fate Therapeutics advances its off-the-shelf cellular immunotherapy platform, showing promise in autoimmune diseases and solid tumors with a strong cash runway through 2027. A shift towards less intensive conditioning regimens is enhancing accessibility.

Tharimmune receives positive FDA feedback on its 24-hour opioid overdose prophylactic, TH104, while simultaneously forging a path in institutional blockchain finance with its Canton Coin treasury strategy. Can this biotech-blockchain hybrid succeed?

Positive Phase II data signals a potential new treatment approach for soft tissue sarcoma, a rare cancer with limited options. Immutep's efti shows promise in early-stage disease, sparking optimism for improved patient outcomes.

Facing past challenges, Palatin Technologies is making strides with a replenished pipeline targeting both common and rare forms of obesity, bolstered by recent funding and strategic partnerships.

Clinical-stage biotech Domain Therapeutics bolsters its leadership with a new CMO as it progresses novel immuno-oncology therapies targeting G protein-coupled receptors. The company's lead candidate, DT-7012, is currently in Phase I/II trials.

Vivani Medical is advancing its ultra-long-acting semaglutide implant, potentially offering a once- or twice-yearly alternative to daily injections for chronic weight management. The company is gearing up for Phase 1 trials and securing funding amidst a booming GLP-1 market.

Phase 3 data for Imunon's IL-12 gene therapy, IMNN-001, signals potential breakthrough in treating advanced ovarian cancer. Can this novel approach overcome the challenges of existing therapies and deliver a much-needed clinical benefit?

Neurvati Neurosciences, backed by Blackstone Life Sciences, appoints Carlos Martin as CCO, signaling a strategic shift towards early commercialization for its pipeline, notably Radiprodil for GRIN-NDD. This move highlights a growing trend of private equity investment in neuroscience.

Positive Phase 2a data and a strengthened financial position position Q32 Bio as a potential disruptor in the alopecia areata space, offering hope for a condition with limited effective therapies.

Positive Phase 2 results for vidofludimus calcium offer a potential breakthrough in progressive multiple sclerosis, but the biotech faces a critical funding challenge to bring the therapy to market.

Despite a Q3 revenue dip, Protalix BioTherapeutics is prioritizing pipeline development, particularly its novel gout treatment, PRX-115, and navigating a competitive landscape for Gaucher disease therapies. Analysts watch closely.

Swedish biotech PeptiSystems has secured growth equity funding to expand its innovative peptide and oligonucleotide manufacturing solutions, tapping into a rapidly expanding market and addressing supply chain vulnerabilities.

Danish biotech Zealand Pharma is rapidly transforming from a research-focused firm to a commercial powerhouse, driven by promising obesity treatments and a major partnership with Roche. New data readouts loom large for 2026.